California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

By Christy Santhosh (Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its ...

A number of sessions on the second day of IPWatchdog LIVE examined the state of U.S. IP policy and the potential for change ...

A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board ...

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

Here's a rundown of some of the multibillion-dollar spending pledges made by companies since President Trump took office. Apple: The iPhone maker pledged to spend more than $500 billion over four ...

People who land in the ER after using hallucinogens are more than twice as likely to die in a handful of years, a new study ...